Cover Image

Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products

We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature,...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmitt, Stefan (Author) , Mailänder, Volker (Author) , Egerer, Gerlinde (Author) , Leo, Albrecht (Author) , Becker, Sven (Author) , Reinhardt, P. (Author) , Wiesneth, M. (Author) , Schrezenmeier, H. (Author) , Ho, Anthony Dick (Author) , Goldschmidt, Hartmut (Author) , Möhler, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 4 March 2008
In: International journal of hematology
Year: 2008, Volume: 87, Issue: 3, Pages: 289-297
ISSN:1865-3774
DOI:10.1007/s12185-008-0055-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12185-008-0055-x
Get full text
Author Notes:S. Schmitt, V. Mailaender, G. Egerer, A. Leo, S. Becker, P. Reinhardt, M. Wiesneth, H. Schrezenmeier, A.D. Ho, H. Goldschmidt, T.M. Moehler
Description
Summary:We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature, we consider pre-transplant Hb level of 11-12 g/dl, platelet count higher than 70/nl, good WHO performance status of two and lower and informed consent as important eligibility criteria. During cytopenia recommended supportive measures include growth factor support with erythropoietin and G-CSF, p.o. iron treatment as well as prophylactic use of anti-fibrinloytic agents. Furthermore we discuss additional options that might be considered depending on the individual factors as e.g. pre-transplant collection and cryoconservation of autologous platelet concentrates. Moreover, an analysis of socio-economic issues regarding this procedure is presented. We conclude that allogeneic blood product free transplantation is a feasible procedure that can be offered to the patients belonging to distinct religious groups refusing allogeneic blood products as Jehova´s Witnesses and patients presenting other contraindications for transfusions.
Item Description:Gesehen am 13.10.2021
Physical Description:Online Resource
ISSN:1865-3774
DOI:10.1007/s12185-008-0055-x

Similar Items